Search
Niraparib
go.drugbank.com/drugs/DB11793ApprovedInvestigationalNiraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. … [L43277] Niraparib was approved by the European Commission on November 16, 2017 [L43742] and by Health Canada on June 27, 2019.
Abarelix
go.drugbank.com/drugs/DB00106ApprovedWithdrawnPraecis announced in June 2006 that it was voluntarily withdrawing the drug from the market.
(+)-Mefloquine
go.drugbank.com/drugs/DB05636Investigationalcompare the efficacy of (+) Mefloquine vs. racemic [Mefloquine]. … (+)-Mefloquine was under investigation in clinical trial NCT00931697 (Study to Investigate the Safety, Tolerability and Pharmacokinetics of AD 452 [(+)-Mefloquine] Compared With Racemic Mefloquine) to
Edaravone
go.drugbank.com/drugs/DB12243ApprovedInvestigational[A19140,L44007,A254257] The intravenous formulation of edaravone was first approved in Japan in 2001 for the treatment of acute ischemic stroke. … [L44007] It was later approved for the treatment of amyotrophic lateral sclerosis (ALS) in Japan and South Korea in 2015, followed by the FDA approval in May 2017 [L41810] and Health Canada approval in
Categories: Compounds used in a research, industrial, or household settingLactose
go.drugbank.com/drugs/DB04465ApprovedInvestigationalWithdrawnA disaccharide of glucose and galactose in human and cow milk. It is used in pharmacy for tablets, in medicine as a nutrient, and in industry.
Mixtures: SYNTHROID® 112 MCG TABLETAS, SERECOR® FORTE DPI 100Categories: Compounds used in a research, industrial, or household settingStreptococcus pneumoniae type 15b capsular polysaccharide antigen
go.drugbank.com/drugs/DB10333ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.
Mixtures: Prevnar 20, PNEUMOVAX 23 Injektionslösung in einer FertigspritzeCeftobiprole
go.drugbank.com/drugs/DB04918ApprovedWithdrawnThe EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion of ceftobiprole medocaril in February 2010, recommending the refusal of its marketing authorization in the European … for skin and skin structure infections and bacteremia in April 2024.
Influenza A virus A/Guangdong-Maonan/SWL1536/2019 CNIC-1909 (H1N1) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB15703ApprovedInvestigationalInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Mixtures: Fluarix Quadrivalent 2020/2021, Fluarix Tetra Injektionssuspension in einer FertigspritzeHolliday junction branch migration complex subunit RuvB
go.drugbank.com/bio_entities/BE0001514TargetThermotoga maritima (strain ATCC 43589 / MSB8 / DSM 3109 / JCM 10099)The RuvA-RuvB-RuvC complex processes Holliday junction (HJ) DNA during genetic recombination and DNA repair, while the RuvA-RuvB complex plays an important role in the rescue of blocked DNA replication … The RuvB hexamer acts as an ATP-dependent pump, pulling dsDNA into and through the RuvAB complex.
Polypeptides: Holliday junction branch migration complex subunit RuvBCytochrome b6-f complex iron-sulfur subunit
go.drugbank.com/bio_entities/BE0002474TargetMastigocladus laminosusComponent of the cytochrome b6-f complex, which mediates electron transfer between photosystem II (PSII) and photosystem I (PSI), cyclic electron flow around PSI, and state transitions.
Polypeptides: Cytochrome b6-f complex iron-sulfur subunit